AstraZeneca PLC (LSE:AZN) said it has sold its manufacturing site in West Chester, Ohio, to National Resilience Inc, which plans to expand the site and support future growth of its medicines manufacturing capabilities.
"As part of our long-term strategy to ensure our global supply network remains fit for the future, we are continuously optimising our manufacturing footprint to meet the evolving needs of our pipeline and portfolio,” commented Andrew Wirths, senior vice president of AstraZeneca’s Americas Supply Region in a statement.
“The transfer of our West Chester site to Resilience will enable the continued supply of AstraZeneca medicines to patients, as well as the continued employment for more than 500 people working at the West Chester site. I'm encouraged by Resilience's plans to transform the site into their drug product centre of excellence," he added.
Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines.
Resilience CEO Rahul Singhvi said: "The West Chester site will play an important role in the delivery of our mission to broaden access to complex medicines, protect biopharmaceutical supply chains, and strengthen domestic preparedness.”
Completion of the sale is expected in the first quarter of 2023, with a phased transition of services.